Skip to content Skip to footer
Subscribe Now
Know Your Investor- Samsara Biocapital (October’24 Edition)
INSIGHTS+

Know Your Investor: Samsara Biocapital (October’24 Edition)

Shots:   A California-based venture capital fund, Samsara Biocapital partners with medical companies and scientists to infuse cutting-edge innovations in medicines   In 2023, Samsara participated in five funding rounds and invested around $2.3B to add 19 companies to its portfolio   For a curated report on a specific investor or venture capital, reach out to us at connect@pharmashots.com …
October 17, 2024

Read more

Disease of the Month – Psoriatic arthritis
INSIGHTS+

Disease of the Month – Psoriatic arthritis

Shots: Psoriatic arthritis is a chronic inflammatory condition characterized by joint pain, stiffness and swelling  In this reprise of our Disease of the Month report, we present an enlightening description of Psoriatic arthritis with a thorough study of epidemiology, market size, disease management, potential medicines, patient advocacy groups, and the key players involved     For a…
October 16, 2024

Read more

Viewpoints_Yelak Biru
VIEWPOINTS

Fund Raising Initiative: Yelak Biru from International Myeloma Foundation in Conversation with PharmaShots

Shots:   As a fund-raising initiative, the International Myeloma Foundation began a 3-day, 2-night cycling expedition from Aug 29thto Sep 3rd  The initiative supports patient education, advocacy, and next-gen research to advance a cure for multiple myeloma  Today, at PharmaShots we have Yelak Biru, President and CEO of the International Myeloma Foundation, shedding light on this…
October 16, 2024

Read more

Viewpoints_Stella Sarraf
VIEWPOINTS

Enhancing Neurodegenerative Care: Stella Sarraf from Spinogenix in an Enlightening Dialogue Exchange with PharmaShots

Shots:  With a broad portfolio of candidates in ALS, Alzheimer’s disease, Schizophrenia, and Fragile X Syndrome, Spinogenix initiated the P-II study evaluating SPG302 for the treatment of patients with Alzheimer’s disease  SPG302, a synaptic regenerative therapy, is aimed to provide an effective and patient-friendly solution as a daily pill for ALS and Alzheimer’s disease  Today…
October 14, 2024

Read more

Countries in Health Innovation Top 20 2024
TOP 20

Top 20 Countries in Health Innovation in 2024

Top 20 Countries in Health Innovation in 2024 Shots: By leveraging high-quality research, PharmaShots brings a meticulously prepared guide to the Top 20 Countries in Health Innovation Using quantitative and qualitative analysis of several aspects encompassing healthcare innovations, PharmaShots dedicatedly navigated the core focus areas of innovations in healthcare while considering trending practices like the…
October 10, 2024

Read more

Thoughtspot_Saurabh Chaubey
THOUGHTSPOT

Finding the Perfect Branding Partner for Your Biopharma Company

Shots:  Branding in the biopharma industry encompasses utilizing market research, brand positioning, understanding the target audience, regulatory compliance, and ensuring reputation and credibility.  An ideal branding partner in the biopharma industry must be the one who has been in your shoes, comes up with innovative curated solutions, and of course, must be an ideal choice…
October 9, 2024

Read more

PharmaShots Magazine - October 2024 Edition
MAGAZINE

PharmaShots Magazine – October 2024 Edition

With globalization bringing countries closer, medical tourism continues to bloom by offering high-quality healthcare provisions outside the domestic healthcare facilities. Medical Tourism aka health tourism offers patients with options to choose the best and budget-friendly healthcare treatment. Millions of medical tourists visit other countries in pursuit of affordable healthcare treatments.   Developing countries remain favorite…
October 9, 2024

Read more

Viewpoints_Dr. Robert Fogel_Janet Franklin_Dr. Dave Singh
VIEWPOINTS

ATS 2024: Robert Fogel, Janet Franklin, and Dave Singh from AstraZeneca & Amgen in Conversation with PharmaShots

Shots:  Recently AstraZeneca and Amgen presented the results in late-breaking session from the COURSE trial, a proof-of-concept study evaluating tezepelumab in COPD  The PoC study was carried out in people with moderately to very severe COPD with a broad range of eosinophil levels  Today, at PharmaShots we have Robert Fogel from AstraZeneca, Janet Franklin from…
October 8, 2024

Read more

Viewpoints_Robert Fogel_Dave Singh
VIEWPOINTS

AstraZeneca at ATS’24: Robert Fogel & Dave Singh in a Stimulating Conversation with PharmaShots

Shots:  Cardiopulmonary events associated with COPD are responsible for an increasing mortality rate in COPD patients. ETHOS trial, a posthoc analysis navigates BGF’s impact on a wide range of cardiopulmonary outcomes beyond COPD exacerbations  The post-hoc analysis reveals that AstraZeneca’s Breztri led to a 20% reduction in the risk of severe cardiopulmonary events. AstraZeneca is currently…
September 30, 2024

Read more

Exclusive_Chris Heery_2024
EXCLUSIVE

Advancing Care for Hematologic Malignancies: Chris Heery from Arcellx in a Stimulating Dialogue Exchange with PharmaShots

Shots:  Arcellx’s Anito-cel, a BCMA CAR-T therapy recently got the FTD, ODD, RMAT designations by the FDA for the treatment of patients with relapsed or refractory multiple myeloma (r/rMM)  Today, at PharmaShots we have Chris Heery, Chief Medical Officer at Arcellx, shedding light on Anito-Cel therapy in advancing care for multiple myeloma  In late 2022,…
September 30, 2024

Read more

Load more